← All trials
NCT06830421
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2023
- Primary completion
- Aug 31, 2029
- Completion date
- Aug 31, 2031
- First posted
- Feb 17, 2025
- Last posted
- Feb 17, 2025
- Enrollment
- 340
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of FreiburgLead sponsor
- German Federal Ministry of Education and ResearchCollaborator
- University of DuesseldorfCollaborator
- University of TuebingenCollaborator
- Ludwig Maximilians UniversityCollaborator
- University of RegensburgCollaborator
- University of TuebingenCollaborator
- University of FreiburgSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.